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Aberrant expression of the islet amyloid polypeptide (IAPP) gene might be involved in the pathogenesis of nun-insulin-dependent diabetes mellitus 
(NIDDM). Here, we report that IAPP promoter-luciferase constructs revealed tissue-specific activity. This activity was not mediated by CAMP. 
Sequential 5’ deletions of the IAPP promoter caused a progressive derepression of the IAPP gene promoter in IAPP-producing cells. Comparison 
of the nucleotide sequence of the IAPP promoter with that of the insulin promoter (both active in pancreatic B-cells) reveals two sequence elements 
of putative importance: an insulin enhancer-like sequence and an element which corresponds to a protected domain in rat insulin I gene promoter 
footprint experiments. 
Human IAPP/amylin gene; Promoter activity; Negative regulation; Pancreatic /I-cell; Diabetes mellitus type 2 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Islet amyloid polypeptide (IAPP) or amylin is a novel 
pancreatic polypeptide hormone which is produced by 
the P-cells of the islets of Langerhans [1,2] and is co- 
secreted with insulin in response to glucose [3,4]. 
Recently, IAPP was detected in human plasma [5,6]. 
IAPP has been implicated in the pathogenesis of non- 
insulin-dependent diabetes mellitus (NIDDM). IAPP is 
the formative protein in amyloid deposited in pan- 
creatic islets of NIDDM patients [2,7] and IAPP has 
been shown to cause insulin-resistance in vitro [8,9] and 
in vivo [lO,ll]. Both islet amyloid and insulin- 
resistance are characteristic pathological features of 
NIDDM. 
2.1. Plasmids 
Superluc (pSL) was made by replacing the HindIII-NpaI fragment 
of superCAT containing the CAT gene by a HindIll-BamHI frag- 
ment of pDRlO1 [15] (gift from Dr P. Oudshoorn, Utrecht, The 
Netherlands) containing the firefly luciferase gene. pRSVluc contains 
the LTR of RSV (AccI-Hind111 fragment) upstream of the luc gene. 
The IAPP promoter constructs (Fig. 1) are derived from the genomic 
clone hh201 [12]. Construct 1 corresponds to a TaqI-Hind111 frag- 
ment. Constructs 2-6 were made by PCR using the following 
oligonucleotide primers: 
-800: 5 ’ -GCATCTAAGCTTCTACAAAGTACTGTGTGAGCT- 
AA-3 ’ 
-390: 5’.ATTGAGGTCACTTGGGTTCA-3 ’ 
We have determined the nucleotide sequence of the 
human IAPP gene and found no evidence for the 
assumption that a mutated form of IAPP is present in 
islet amyloid [12,13]. We now study the regulation of 
IAPP gene expression, since IAPP may be abnormal in 
quantity in NIDDM patients which could be due to 
overexpression of the IAPP gene. Expression of the 
IAPP gene, like that of the insulin gene, may be limited 
to pancreatic P-cells and insulinomas [12,14]. In this 
paper, we report studies on the promoter activity of the 
5’-upstream region of the IAPP gene in different cell 
types using luciferase as a reporter gene. These studies 
provide evidence for negative regulation of the IAPP 
gene promoter. 
- 189: 5 ‘-ACTGTGTATTTGCTACGTTA-3 ’ 
+32: 5 ’ -GAGTCCAAGCTTGTATCCACTGGAATA-3 ’ 
ATG: 5 ’ -GGATGCCCATGGCTTCTCAAATTTTCTGCAAA-3 ’ 
ATGA: 5 ’ -GGATGCCCATGGCTTCTCAAATTTTCTTTTAAT- 
GTTTCAATGTCA-3 ’ 
The HindIII, NcoI (both underlined) or SmaI sites were used for 
cloning PCR-fragments into pSL. In the ATG and ATGA constructs 
a point mutation was introduced in order to create a NcoI site 
(CCATGG, genomic sequence is C&ATGG). mRNAs from these 
constructs contain the same untranslated leader as prepro-IAPP 
mRNA. All plasmids were purified twice over CsCl-gradients. 
2.2. Cell culture, DNA transfections and luciferase assay 
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KIN AHT2 cells (insulin-secreting subclone of the rat insulinoma 
cell line RIN-m5F, a gift from Dr B. Roep, Leiden, The Netherlands) 
were cultured in RPM1 1640, 293 cells (human embryonal kidney cell 
line) were cultured in DMEM, both media contained 10% fetal calf 
serum and 0.03% glutamine. On a Northern blot containing RNA 
from RIN cells, we detected both insulin and IAPP poly A’ RNAs 
(not shown). RIN cells were transfected by electroporation (Gene- 
Pulser, Biorad). 5 million cells in 0.4 ml serum-free RPM1 1640 were 
mixed with DNA in gene pulser cuvettes. Following the administra- 
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tion of’ current (250 V, 500 /cF, room temperatut-e) cells were allowed 
to recover for several minutes before transferring them into T-25 
flasks with serum-containing medium. 293 cells were transfected by 
calcium-phosphate coprecipitation. After 4 h cells were exposed to 
10% DMSO for 30 5. After 24 h RIN or 293 cells were rinsed once 
with PBS and the cells were lysed in 250 /II lysis buffer (25 mM Tris- 
phosphate (pH 7.8), 8 mM MgCI~, I mhl DTT, 1% Triton X-100, 
15% glycerol). 
The luminometer (Lumac, 3M) injected IOOpf of I mM luciferin 
(Sigma) and I mM ATP in lysis buffer into an appropriate volume 
of lysate and measured tight production. In order to normalize 
luciferase activities for cell number, the protein content of the lysate 
was determined [16]. 
3. RESULTS AND DISCUSSION 
In Fig. 1 the IAPP gene promoter-luciferase con- 
structs are schematically represented and the relative 
luciferase activity in RIN cells (IAPP-producing) and 
293 cells (non-IAPP-producing) is shown. Surprisingly, 
the construct -800/+32, which contains a large 
5 ‘-upstream region of the IAPP gene, has very low ac- 
tivity in RIN cells. The activity of - 8001ATG fcontain- 
ing exon 1, intron 1 and exon 2 up to ATG 
translation-initiation codon) is 2-3-fold higher. This 
enhancement is not due to increased mRNA stability, 
since the ‘pre-spliced’ construct (-800/ATGA, in 
which intron 1 is specifically removed) shows low 
Iuciferase activity. One e~p~ar~ation for the effect of the 
intron is that the association of pre-mRNAs with the 
splicing-machinery facilitates mRNA transport to the 
cytoplasm [17]. Alternatively, intron 1 sequences may 
enhance IAPP gene transcription in RIN cells. 
The removal of the region -800 to --I89 of the 
IAPP promoter increases promoter activity 5-&fold. 
This suggests that elements within this region (especial- 
ly in the region -390 to - 189) are involved in repres- 
sion of IAPP promoter activity. 
In 293 ceils the activity of IAPP promoter constructs 
-SOO/ATG and -390/‘ATG is efficiently suppressed 
when compared to the activities in RIN cells {Fig. 1). 
Apparently, the IAPP promoter is inactive in non- 
IAPP-producing cells. This may be due to the absence 
of tissue-specific frans-acting factors which are 
necessary for lAPP promoter activation or to the 
xesence of transcripotional repressors. The derepres- 
.;ion of the IAPP promoter in RIN cells (-189/A’PG) 
is also observed to some extent in 293 cells, aithough in 
absolute terms the activity is still low. It can be 
hypothesized that repression of the IAPP promoter is 
found in many cell types. It may be that this negative 
regulation is overruled in $-cells by tissue-specific 
positive tratrs-acting factors, as has been hypothesized 
for the insulin promoter [lg]. For the rat insulin 1 pro- 
moter, negative regulation in non-pancreatic cells has 
been described, which is thought to be mediated by a 
i.6acting element in the region -219 to -103 [lS]. 
The nucleotide sequence TGATGTCA in the IAPP 
promoter (-61 to -54) resembles a CAMP-responsive 
element (CRE with a C to T substitution (underlined) 
Exon 1 Ex0n2 
Relative luclferase act&& 
3 2 1# 
(% pRSVluc) per 118 protein 
4 
i-+ 100 nucl H,nd III A?G FUN RIN 293 
CanstnJct 25w 5OKl low 
-iiooi~-404 1. 0.5 0.3 0.1 
-800 2. 0.6 0.7 0.1 
-800 1.8 2.0 0.2 
-800 0.3 0.8 0.5 
1.9 7.0 0.2 
8.2 13.0 0.9 
no insert 7. 0.3 0.5 0.1 
1 
Fig. 1. Schematical representation of 5’-flanking IAPP sequences present in different luciferase constructs and relative Iuciferase actisities of 
these constructs in RIN cells and 293 cells. Constructs were made as described in section 2. Indicated are (1) TATA-box, (2) EZ-domain and (3) 
insulin enhancer-like sequence. Reporter gene activity is expressed relative to that of pRSVluc and was normalized for cell number (protein content 
of lysate). Luciferase activities after transfection of 293 cells (two independent duplicate experiments) were very reproducible (SD less than 15%). 
Indicated are the mean values of one duplicate experiment. Transfections of RIN cells by electroporation was performed 4 times with 25 pg, 4 
times with 50 pg and 3 times with 100 ,~g DNA. Indicated are the mean of representative duplicate experiments with 25 pg or uzith 50 iirg DNA. 
The variability of RIN cell transfections was higher than in 293 celis (SD between 10 and 60%). however. the pattern of responses was very 
consistent in all e~perinlents. 
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Table I Table II 
Effect of dibutyryl CAMP (1 mM) and forskolin (lo-” M) on relative 
promoter activities of constructs -8OO/ +32, -8OO/ATG and 
- 189/ATG in RIN cells 
Comparison of the EZ-domain-like sequences in the 5’upstream 
regions of the IAPP genes in man (this report) and rat (A.D.M. van 
Mansfeld et al., Biochim. Biophys. Acta, in press) and in the insulin 
genes of man, rat (1 and 11) and mouse (I) 1301 
Luciferase activity is expressed relative to that of pRSVluc and was 
normalized for the protein content of the lysate 
from the consensus equence [191). This sequence in the 
IAPP promoter is probably not a functional CRE 
because neither the addition of dibutyryI-CAMP nor the 
activation of adenylate-cyclase with forskolin resulted 
in a significant increase of promoter activity of the con- 
structs -8OO/-t32, -8OO/ATG or -189/+32 in RIN 
cells (Table I). 
Ferrier et al. reported expression of the rat IAPP 
gene in non-pancreatic tissues, e.g. duodenum and 
stomach [20]. However, the amount of IAPP mRNA in 
these tissues is very low as compared to the amount of 
IAPP mRNA in the pancreatic islets. Within the islets 
IAPP gene expression is limited to the P-cells which in 
addition selectivefy express the insulin gene. 
A comparison of the IAPP promoter (Fig. 2) with 
the insulin promoter reveals two conserved sequence 
elements which might be of importance with respect o 
transcriptional control. First, the nucleotide sequence 
AAGATGGC in the IAPP 5 ‘-upstream sequence 
(-245 to -238, complementary sequence 
GCCATCTT) resembles the insulin enhancer 
GCCATCTG [21]. A similar element (GCCATCAG) is 
rat insulin 1 gene I<---E2 domain---->I 
indicated are the position of these elements relative to the 
transcription-initiation site, and the 18 nucleotide protected domain 
of the rat insulin I promoter in footprint experiments 1261 
present in the &cell-specific promoter of the rat 
glucokinase gene [22]. The insulin enhancer activates 
the insulin promoter in P-cells and is capable of driving 
a heterologous promoter in a tissue-specific manner 
1231. We will refer to this putative IAPP promoter ele- 
ment as the ‘IAPP-Far’-box because its position 
relative to the site of initiation of transcription is 
similar to that of the Far-box in the rat insulin I gene 
promoter [24]. It remains to be established whether the 
IAPP-Far-box is involved in the negative regulation 
that is attributed to elements within the region -390 to 
-189. The insulin enhancer in the rat insulin II gene 
promoter is involved in both positive and negative 
transcription regulation [25]. 
The second interesting element is a sequence of 19 
nucleotides in the human and rat IAPP promoters and 
in the insulin promoters of man, rat and mouse (Table 
II). Intriguingly, this conserved element corresponds 
exactly to a protected region (E2) of the rat insulin I 
promoter in footprint experiments [26,27]. Ohlsson 
-1100 TCGAGhCCAG CCTGACCAAC ATAGAGAATC CCGTCTCCAC TAAAAATACA AAATTAGCUL TACATGGTGA TGCATGCCTG TAATCCCAGC TACKTGTAG 
-1000 GCTGAGGCAG GAGw.TCACI TGAACCCGGG AGGCACAGGT TACAGTGAGC CGAGATfGCA CCC!lTGfAclf CCAGCCTGGG CAACAAAGAG TGAAACTXA 
- 900 TCI’CAAAAAA AAAGAAAAAA AAAGAAAGAG AGAAAGAAAT ACAAGAARAA GAAAAAGCAA Tl-XGAGAAP. !l-FXAAXiGC AAATCATlTT AAAAGACAAA 
- 800 CTACAAAGTA CTGTGl!GAGC TAAGCCATTC ATAATGTTCT CATGGAGCTA AT GGGAEXA AATCTGTTCT XCAAAATAA TTGTAAAATT TCTGTGTAAG 
- 700 AATGAATGGA AAAGGTCATC CAA?.AACTAC TTGACTACAT ATACCTATGG ATCTCTATCT AAGTGCTGAA AAATGAATTP TTI’TATTCAT TTGGTTATCP 
- 600 AGCATTTGTT CATT’XAATT TTGmTGPP CCCTGTCATA TCTCTGGTAC CTAGAATAAT CCCTACCACA GAGPAGGTCT TCCATTACK TTATGC’FXT’I 
- 500 AAATCTCCCC TCACCTCATT GTAAATGACT TTTGATi?KY CTMTATGCC CTTI’TTATAC ACCTTTCCeT TATATCTCCA T’FIATTCCI’G AAGCTI’CATG 
- 400 GGATTCAGCC ATTGAGGI!CA CITGGGplTA GATATACCAA AAGI’CTGTGA TTTCTCTGTT TGCATATATG CACAT-ITGTT GTTATCCTTA CCCFTTTCI’A 
- 300 TU?r=PTCCTT ACCATAXAT ACACl-l’AATT CTT~TP CACTCATGTC T’I’ACAAAGAT GCXAAATTCA AACTTCTGCT GTGTATGACA CACCATTAAC 
- 200 TGCACAAGGA CACTGTGTAT TTGCPACGTP AATA’I-FI’ACP GATGAGPPAA TGTAATAATG ACCCATCCGC TPCTGCPGCC TGTGAGCXAC TTTCTATCTA 
- 100 TAGGGATGGA AATTAATGAC AGAGGCKTC TGAGCTGCCT GATGTCAGAG CTGAGAAAGG TGTGAGGGGT ATATAAGAGC TGGATTACTA GTTAGCAUT 
1 GAGGGGGTAA ATATPCCA~ 
Fig. 2. Nucleotide sequence of the 5’-upstream region (-i 100 to +20) of the human IAPP gene, Nucleotides - 1100 to -896 represent part of 
an Alu-repetitive sequence. Underlined are the IAPP-Far-box (-245 to -238), the E2-domain-like sequence (-155 to -137), the (IRE-like 
sequence (-61 to -54), the TATA-box (-31 to -25) and the cap-site (+ I). The numbering is relative to the mapped 5’ end of exon 1 ([29]; 
J.W.M.H., unpublished results). 
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and Edlund [26] describe non-identical protection of 
the E2-domain upon incubation with nuclear extracts 
from HIT (hamster islet tumor) or BHK (baby hamster 
kidney) cells, suggesting that different tissue-specific 
proteins might recognize this element. It may well be 
that identical or similar trans-acting factors involved in 
,&cell-specific gene transcription can bind to this ele- 
ment in the IAPP and insulin promoters, respectively. 
In addition to the sequence elements mentioned 
above, the IAPP promoter contains a 12 basepair motif 
with perfect dyad symmetry, TGCATATATGCA 
(-340 to -329). To our knowledge this sequence does 
not resemble any known element involved in transcrip- 
tion regulation. Furthermore, the sequence TGCCTGA 
(-65 to -59) resembles the nucleotide sequence 
CGCCTGA of the protein binding A-domain of the so- 
called ‘islet cell enhancer’ that was recently identified in 
the glucagon gene promoter [28]. 
A mutational analysis of these putative transcrip- 
tional control elements must reveal whether or not they 
are true c&acting elements. The conservation of an in- 
sulin enhancer-like sequence and an E2-domain-like se- 
quence in the IAPP and insulin promoters justifies 
further research on their putative role in pancreatic ,8- 
cell-specific gene expression. 
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